PHAR
$15.17-0.26 (-1.69%)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RU...
Recent News
Pharming Group (PHGUF) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Pharming Group (PHGUF) reports a robust 27% annual revenue increase, while navigating competitive pressures and regulatory hurdles.
Pharming Group Q4 Earnings Call Highlights
Pharming Group (NASDAQ:PHAR) reported what management described as a strong finish to 2025, highlighting double-digit revenue growth, a return to operating profitability, and expanding commercial traction for both RUCONEST and Joenja during its fourth-quarter and full-year 2025 earnings call. 2025
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday as Traders React to Oil Supply Risks From Iran Conflict
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.6% and the actively tr
Assessing Pharming Group (ENXTAM:PHARM) Valuation After A Strong 1-Year Shareholder Return
Why Pharming Group Is On Investors’ Radar Today Pharming Group (ENXTAM:PHARM) has attracted attention after recent price moves, with the share price around €1.35 and a mixed pattern of returns over the past week, month and past 3 months. For investors, the key question now is how this recent trading performance lines up with Pharming Group’s current profitability, revenue profile and value characteristics. See our latest analysis for Pharming Group. While the 1-day and 30-day share price...
Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards?
PHAR heads into Q4 results, with Ruconest and Joenja sales in focus, pipeline updates looming, and investors eyeing clarity on key regulatory setbacks.